Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
VANCOUVER, British Columbia, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc.
Cytokinetics ( CYTK ) Reports Q2 Loss, Tops Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of +16.42% and +1,658.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CYTK Earnings Jump 3,065%
Cytokinetics ( NASDAQ:CYTK ) , a late-stage biopharmaceutical company focused on cardiovascular disease, reported earnings for Q2 FY2025 on August 7, 2025. The headline news was a dramatic outperformance on GAAP revenue: it booked $66.8 million in GAAP revenue, compared to analyst expectations of ...
Techne ( TECH ) Beats Q4 Earnings and Revenue Estimates
Techne (TECH) delivered earnings and revenue surprises of +6.00% and +0.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics to Announce Second Quarter Results On August 7, 2025 - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., July 24, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced that it is scheduled to report second quarter results on August 7, 2025 at 4:00 PM Eastern Time.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( C ) ( 4 ) - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., July 18, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units ( RSUs ) that will be settled in shares of ...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( C ) ( 4 )
SOUTH SAN FRANCISCO, Calif., July 18, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated ( Nasdaq: CYTK ) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units ( RSUs ) that will be settled ...
Zymeworks ( ZYME ) Surges 7.1%: Is This an Indication of Further Gains?
Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
Hot Line Presentation of MAPLE-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy ...
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 - Cytokinetics ( NASDAQ:CYTK )
Hot Line Presentation of MAPLE-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Aficamten in Obstructive Hypertrophic ...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., June 17, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced that on June 15, 2025 it granted stock options to purchase an aggregate of 83,583 shares of common stock and 56,334 restricted stock units ( RSUs ) that will be settled in shares of ...
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - CYTK
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations ...
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program
Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values ...
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program - Cytokinetics ( NASDAQ:CYTK )
Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 4th, 2025 SOUTH SAN FRANCISCO, Calif., June 10, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced a call for proposals for its annual Cytokinetics ...
Cytokinetics ( CYTK ) Down 1.9% Since Last Earnings Report: Can It Rebound?
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cytokinetics to Participate in the Jefferies Global Healthcare Conference - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., May 29, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced that members of the Company's management team are scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 9:20 AM ...
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress - Cytokinetics ( NASDAQ:CYTK )
Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions HEOR Analyses of Real-World Data Reveal Disparities in Outcomes In Females and Older Patients with Non-Obstructive HCM
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress
Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patientswith Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions ...
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress
Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions HEOR Analyses of Real-World Data Reveal Disparities in Outcomes In Females and Older Patients with Non-Obstructive HCM
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., May 16, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 shares of common stock and 27,144 restricted stock units ( RSUs ) that will be settled in shares of ...
Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology
Second Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field ...
Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology - Cytokinetics ( NASDAQ:CYTK )
Second Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field
Cytokinetics Unusual Options Activity - Cytokinetics ( NASDAQ:CYTK )
Investors with a lot of money to spend have taken a bearish stance on Cytokinetics CYTK. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Cytokinetics Announces Positive Topline Results From MAPLE-HCM - Cytokinetics ( NASDAQ:CYTK )
Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., May 08, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European Society of Cardiology, taking place in Belgrade, ...
Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended
CYTK reports narrower-than-expected Q1 loss. However, the target action date for aficamten in obstructive HCM has been extended by the FDA to provide time for reviewing a REMS submission made at the agency's request.
Cytokinetics ( CYTK ) Reports Q1 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of 3.55% and 26.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update - Cytokinetics ( NASDAQ:CYTK )
PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2025
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months - Cytokinetics ( NASDAQ:CYTK )
FDA extended aficamten's PDUFA date to Dec. 26, citing REMS review. No new clinical trials or data have been requested by the FDA. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in volatile markets.
Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Apple ( NASDAQ:AAPL ) , Advantage Solutions ( NASDAQ:ADV )
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday. Shares of Block, Inc. XYZ fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter financial results.
Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced that the U.S.
Cytokinetics to Participate in May Investor Conferences - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., April 30, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced that the Company is scheduled to participate in the following investor conferences in May:
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - Cytokinetics ( NASDAQ:CYTK ) , ACCESS Newswire ( AMEX:ACCS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Cytokinetics to Announce First Quarter Results on May 6, 2025 - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., April 22, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced that it is scheduled to report first quarter results on May 6, 2025 at 4:00 PM Eastern Time.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., April 17, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced that on April 15, 2025 it granted stock options to purchase an aggregate of 60,670 shares of common stock and 40,888 restricted stock units ( RSUs ) that will be settled in shares of ...
Applied Digital Posts Weak Revenue, Joins Allegro MicroSystems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Applied Digital ( NASDAQ:APLD ) , Allegro Microsystems ( NASDAQ:ALGM )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Tuesday. Shares of Applied Digital Corporation APLD fell sharply in today's pre-market trading following weak quarterly revenue.
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO
- Led by new investor Deep Track Capital, with participation from AN Ventures, Catalio Capital Management, Cytokinetics, Inc. and existing investors RA Capital Management and SV Health Investors -
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday - Arcellx ( NASDAQ:ACLX ) , Allegiant Travel ( NASDAQ:ALGT )
U.S. stocks were lower, with the Dow Jones index falling over 100 points on Wednesday. Shares of Cognyte Software Ltd. CGNT rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results.
Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., March 31, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced that members of the Company's management team are scheduled to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at ...
Cytokinetics ( CYTK ) Moves 5.4% Higher: Will This Strength Last?
Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday - Agilon Health ( NYSE:AGL ) , Adaptive Biotechnologies ( NASDAQ:ADPT )
U.S. stocks were lower, with the Dow Jones index falling around 400 points on Friday. Shares of Scholastic Corporation SCHL rose sharply during Friday's session following upbeat quarterly earnings. Scholastic reported quarterly losses of 5 cents per share which beat the analyst consensus ...
Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community - Cytokinetics ( NASDAQ:CYTK )
Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to Care
Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community
Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to Care ...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., March 18, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced that on March 14, 2025 it granted stock options to purchase an aggregate of 58,631 shares of common stock, 38,068 restricted stock units ( RSUs ) that will be settled in shares of ...
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo - Cytokinetics ( NASDAQ:CYTK )
New Analyses Related to Aficamten Expand on its Metabolism Pathways, Treatment Effect Associated with Combination Therapy with Disopyramide and Longer-Term Effect on Cardiac Structure and Function
Cytokinetics to Participate in March Investor Conferences - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., March 03, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced that the company is scheduled to participate in the following investor conferences in March: Leerink Global Biopharma Conference: Robert I.
Smart Money Is Betting Big In CYTK Options - Cytokinetics ( NASDAQ:CYTK )
High-rolling investors have positioned themselves bearish on Cytokinetics CYTK, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
